Label: METRONIDAZOLE gel
- NDC Code(s): 71589-014-45, 71589-014-55, 71589-014-60
- Packager: Aleor Dermaceuticals Limited
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Updated December 16, 2021
If you are a consumer or patient please visit this version.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use METRONIDAZOLE GEL safely and effectively. See full prescribing information for METRONIDAZOLE GEL.
METRONIDAZOLE gel, for topical use Initial U.S. Approval: 1963
INDICATIONS AND USAGE
Metronidazole gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Gel, 1%. (3)
Metronidazole gel is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in this formulation. (4)
WARNINGS AND PRECAUTIONS
- Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Although not evident in clinical trials for topical metronidazole, peripheral neuropathy has been reported with the post approval use. The appearance of abnormal neurologic signs should prompt immediate reevaluation of metronidazole gel therapy. (5.1)
- Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of, blood dyscrasia. (5.2)
- If dermatitis occurs, patients may need to discontinue use. (5.3)
- Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. (5.4)
Most common adverse reactions (incidence > 2%) are nasopharyngitis, upper respiratory tract infection, and headache. (6)
To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when metronidazole gel is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption. (7)
See 17 for PATIENT COUNSELING INFORMATION.
Table of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Neurologic Disease
Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Although not evident in clinical trials for topical metronidazole, peripheral neuropathy has been reported with the post approval use. The appearance of abnormal neurologic signs should prompt immediate reevaluation of metronidazole gel therapy. Metronidazole should be administered with caution to patients with central nervous system diseases.
5.2 Blood Dyscrasias
5.3 Contact Dermatitis
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a controlled clinical trial, 557 patients used metronidazole gel, 1% and 189 patients used the gel vehicle once daily for up to 10 weeks. The following table summarizes selected adverse reactions that occurred at a rate of ≥1%:
Table 1: Adverse Reactions That Occurred at a Rate of ≥1% System Organ Class/Preferred Term
Metronidazole Gel, 1%
Patients with at least one AE
Number (%) of Patients
Infections and infestations
Upper respiratory tract infection
Urinary tract infection
Musculoskeletal and connective tissue disorders
Basal cell carcinoma
Nervous system disorders
Respiratory, thoracic and mediastinal disorders
Skin and subcutaneous tissue disorders
Table 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline Metronidazole Gel, 1%
The following additional adverse experiences have been reported with the topical use of metronidazole: skin irritation, transient redness, metallic taste, tingling or numbness of extremities, and nausea.
6.2 Postmarketing Experience
The following adverse reaction has been identified during post approval use of topical metronidazole: peripheral neuropathy. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.
7 DRUG INTERACTIONS
Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when metronidazole gel is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.
8 USE IN SPECIFIC POPULATIONS
There are no adequate and well-controlled studies with the use of metronidazole gel in pregnant women.
Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of metronidazole in rats or mice at 200 and 20 times, respectively, the expected clinical dose. However, oral metronidazole has shown carcinogenic activity in rodents. Because animal reproduction studies are not always predictive of human response, metronidazole gel should be used during pregnancy only if clearly needed.
8.3 Nursing Mothers
After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels taken after topical metronidazole application are significantly lower than those achieved after oral metronidazole a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the risk to the infant.
8.5 Geriatric Use
Sixty-six subjects aged 65 years and older were treated with metronidazole gel, 1% in the clinical study. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
- 10 OVERDOSAGE
Metronidazole gel USP, 1% contains metronidazole, USP. Chemically, metronidazole is 2-methyl-5-nitro-1 H-imidazole-1-ethanol. The molecular formula for metronidazole is C6H9N3O3. It has the following structural formula:
Metronidazole has a molecular weight of 171.16. It is a white to pale yellow crystalline powder. It is slightly soluble in alcohol and has solubility in water of 10 mg/mL at 20˚C. Metronidazole belongs to the nitroimidazole class of compounds.
Metronidazole gel USP, 1% is a clear, colorless to pale yellow, aqueous gel; each gram contains 10 mg of metronidazole in a base of betadex, edetate disodium, hydroxyethyl cellulose, methylparaben, niacinamide, phenoxyethanol, propylene glycol, propylparaben and purified water.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Topical administration of a one gram dose of metronidazole gel to the face of 13 patients with moderate to severe rosacea once daily for 7 days resulted in a mean ± SD Cmax of metronidazole of 32 ± 9 ng/mL. The mean ± SD AUC(0 to 24) was 595 ± 154 ng*hr/mL. The mean Cmax and AUC(0 to 24) are less than 1% of the value reported for a single 250 mg oral dose of metronidazole. The time to maximum plasma concentration (Tmax) was 6 to 10 hours after topical application.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In several long-term studies in mice, oral doses of approximately 225 mg/m2/day or greater (approximately 37 times the human topical dose on a mg/m2 basis) were associated with an increase in pulmonary tumors and lymphomas. Several long-term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses >885 mg/m2/day (144 times the human dose).
Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohn's disease who were treated with 200 to 1200 mg/day of metronidazole for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohn's disease treated with the drug for 8 months.
In one published study, using albino hairless mice, intraperitoneal administration of metronidazole at a dose of 45 mg/m2/day (approximately 7 times the human topical dose on a mg/m2/day basis) was associated with an increase in ultraviolet radiation-induced skin carcinogenesis. Neither dermal carcinogenicity nor photocarcinogenicity studies have been performed with metronidazole gel or any marketed metronidazole formulations.
14 CLINICAL STUDIES
In a randomized, vehicle-controlled trial, 746 subjects with rosacea were treated with metronidazole gel, 1% or gel vehicle once daily for 10 weeks. Most subjects had "moderate" rosacea at baseline. Efficacy was determined by recording reduction in inflammatory lesion counts and success rate in the Investigator Global Assessment (percentage of subjects "clear" and "almost clear" of rosacea at the end of the study). The scale is based on the following definitions:
Table 3: Investigator Global Assessment Scale Score
No signs or symptoms present; at most, mild erythema
Very mild erythema present. Very few small papules/pustules
Mild erythema. Several small papules/pustules
Moderate erythema. Several small or large papules/pustules, and up to 2 nodules
Severe erythema. Numerous small and/or large papules/pustules, up to several nodules
Table 4: Inflammatory Lesion Counts and Global Scores in a Clinical Trial of Rosacea Metronidazole Gel, 1%
Results N (%)
Results N (%)
Baseline, mean count
Week-10, mean count
Investigator Global Assessment
Subject clear or almost clear
Subject with no change
Subjects treated with metronidazole gel, 1% experienced a mean reduction of 9.4 inflammatory lesions in the Week-10 LOCF group, compared to a reduction of 5.6 for those treated with vehicle, or a difference in means of 3.8 lesions.
The contribution to efficacy of individual components of the vehicle has not been established.
16 HOW SUPPLIED/STORAGE AND HANDLING
45 gram tube- NDC 71589-014-45
60 gram tube- NDC 71589-014-60
55 gram pump- NDC 71589-014-55
Storage Conditions: Store at 20˚ to 25˚C (68˚ to 77˚F); excursions permitted between 15˚ and 30˚C (59˚ and 86˚F) [see USP controlled room temperature].
17 PATIENT COUNSELING INFORMATION
- This medication is to be used as directed.
- It is for external use only.
- Avoid contact with the eyes.
- Cleanse affected area(s) before applying metronidazole gel.
- This medication should not be used for any condition other than that for which it is prescribed.
- Keep out of reach of children.
- Patients should report any adverse reaction to their physicians.
Aleor Dermaceuticals Ltd.,
Karakhadi, Vadodara 391450, India.
Aleor Dermaceuticals Ltd.,
Karakhadi, Vadodara 391450, India.
Mfg. License No.: G/25/2216
- PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:71589-014 Route of Administration TOPICAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength METRONIDAZOLE (UNII: 140QMO216E) (METRONIDAZOLE - UNII:140QMO216E) METRONIDAZOLE 10 mg in 1 g Inactive Ingredients Ingredient Name Strength BETADEX (UNII: JV039JZZ3A) EDETATE DISODIUM (UNII: 7FLD91C86K) METHYLPARABEN (UNII: A2I8C7HI9T) NIACINAMIDE (UNII: 25X51I8RD4) PHENOXYETHANOL (UNII: HIE492ZZ3T) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PROPYLPARABEN (UNII: Z8IX2SC1OH) WATER (UNII: 059QF0KO0R) HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) (UNII: ZYD53NBL45) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:71589-014-45 1 in 1 CARTON 09/07/2021 1 45 g in 1 TUBE; Type 0: Not a Combination Product 2 NDC:71589-014-60 1 in 1 CARTON 09/07/2021 2 60 g in 1 TUBE; Type 0: Not a Combination Product 3 NDC:71589-014-55 1 in 1 CARTON 09/07/2021 3 55 g in 1 BOTTLE, PUMP; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA212646 09/07/2021 Labeler - Aleor Dermaceuticals Limited (871411532) Registrant - Aleor Dermaceuticals Limited (871411532) Establishment Name Address ID/FEI Business Operations Aleor Dermaceuticals Limited 871411532 MANUFACTURE(71589-014) , ANALYSIS(71589-014)